Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States

George, Daniel J.; Sartor, Oliver; Miller, Kurt; Saad, Fred; Tombal, Bertrand; Kalinovský, Ján; Jiao, Xiaolong; Tangirala, Krishna; Sternberg, Cora N.; Higano, Celestia S.

doi:10.1016/j.clgc.2019.12.019

Cited by 131 publications

(130 citation statements)

References 23 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…3). Similar results were observed in the analysis of a contemporaneous patient population by George et al [10]. Reasons for the limited use of available treatment options warrant further exploration including an explorations of patient preferences for sequencing treatments and the financial burden of sequencing multiple treatments.…”

Section: Discussionsupporting

confidence: 78%

“…Research examining the survival outcomes of the second-generation ASPIs and sipuleucel-T in a large cohort of treated mCRPC patients has not been performed [7]. While a clinical trial can provide useful information, limitations include the understanding of real-world effectiveness of treatment in a heterogeneous population [8][9][10]. Real-world evidence research provides data that are complementary to clinical trials: effectiveness vs. efficacy and realworld risk:benefit assessments, to start [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

“…In the US, healthcare for a life-threatening disease such as cancer, diagnosis, and treatment will typically occur across multiple medical professionals, pharmacies, and treatment centers leading to discontinuous medical records [10]. Electronic health records can offer a breadth of clinical data yet still with a certain level of missing data and percentage of patients being lost to follow-up.…”

Section: Introductionmentioning

confidence: 99%

“…Electronic health records can offer a breadth of clinical data yet still with a certain level of missing data and percentage of patients being lost to follow-up. One example is a study published by George et al [10]. This study described survival outcomes and treatment patterns using electronic health records from oncology clinics for men with mCRPC covered by a variety of payers and leaving outcomes from urology clinics [10].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer

et al. 2020

View full text Add to dashboard Cite

Introduction: Since sipuleucel-T approval in 2010, the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) now includes the androgen-receptor signaling pathway inhibitors (ASPIs) abiraterone acetate or enzalutamide. In 2013 and 2014, these oral agents were approved for use in men with metastatic prostate cancer who had minimal to no symptoms. We compared overall survival (OS) in men who received their first mCRPC treatment using the Medicare Fee-for-Service 100% administrative claims research dataset with patient-level linkage to the National Death Index. Methods: This retrospective cohort analysis (January 2013 to December 2017) included men who were chemo-naïve at treatment start in 2014 and who had continuous Medicare Parts A, B, and D eligibility during the 3-year observation period. We compared: first-line sipuleucel-T vs. first-line ASPIs and any-line sipuleucel-T vs. any-line ASPIs (without sipuleucel-T). We used a multivariable regression model to help control for potentially confounding factors while assessing survival outcomes. Results: The model included 6044 eligible men (average age 75-78 years) with similar disease severity; [ 80% were white. Median OS, presented as sipuleucel-T vs. ASPI, was 35.2 vs.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Despite these findings, ART-to-ART sequential therapy after castration resistance is often used in clinical practice 29 because ART can be conveniently administered orally and has fewer adverse events;…”

Section: Discussionmentioning

confidence: 99%

The clinical benefit of sequential therapy with androgen receptor axis‐targeted agents alone in patients with castration‐resistant prostate cancer: A propensity score‐matched comparison study

et al. 2020

View full text Add to dashboard Cite

Background: The optimal sequential therapy for castration-resistant prostate cancer (CRPC) remains unknown. In recent years, some doubts have emerged regarding the clinical benefit of sequential therapy with androgen receptor axistargeted agents (ART) such as abiraterone (ABI) or enzalutamide (ENZ) for patients with CRPC. We compared the effect of ART-to-ART (AA) sequential therapy after castration resistance with that of docetaxel (DTX)-combined sequential therapy (ART to DTX or DTX to ART) in patients with CRPC. Methods: We retrospectively identified and analyzed the data of 315 patients with CRPC treated in our seven affiliated institutions between 2009 and 2019. All patients received either DTX or ART (ABI or ENZ) as the first-or second-line therapy after castration resistance. We compared the overall survival (OS) and the second progression-free survival (PFS2), calculated from the initiation of first-line therapy after castration resistance, between the AA sequence group and the DTX-combined sequence group. PFS2 was defined as the period from the start of first-line treatment after castration resistance to progression on second-line treatment. To minimize selection bias from possible confounders, we performed propensity score matching using one-to-one nearest neighbor matching without replacement. Results: Overall, 106 and 209 patients were administered the AA sequential therapy and DTX-combined sequential therapy, respectively. The clinicopathological variables of patients were well balanced after propensity score matching, and there were no significant differences between the two groups. In the propensity scorematched cohort, OS was not significantly different between the two groups (median, 37.9 vs. 45.4 months; hazard ratio [HR], 1.10; 95% confidence interval [CI], 0.68-1.79; p = .701), while PFS2 was significantly shorter in the AA group than in

show abstract

Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone

et al. 2022

View full text Add to dashboard Cite

IMPORTANCEProspective evidence suggests abiraterone is associated with superior progressionfree survival for African American men compared with non-Hispanic White men with metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE To investigate differences in outcomes with first-line abiraterone therapy betweenAfrican American and non-Hispanic White men with mCRPC in a national real-world cohort. DESIGN, SETTING, AND PARTICIPANTSThis retrospective cohort study used a nationwide electronic health record-derived database of 3808 men receiving first-line therapy for mCRPC

show abstract

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States

Cited by 131 publications

References 23 publications

A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer

A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer

The clinical benefit of sequential therapy with androgen receptor axis‐targeted agents alone in patients with castration‐resistant prostate cancer: A propensity score‐matched comparison study

Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone

Contact Info

Product

Resources

About